Grifols Family and Brookfield Resume Talks for Potential OPA Above €10.50 After 2024 Negotiations, Minority Shareholders Support

The Grifols family and Brookfield have resumed discussions regarding a potential takeover bid (OPA) for the pharmaceutical company Grifols. This follows previous negotiations in 2024 that did not result in an agreement. The Grifols family is reportedly seeking a bid price higher than the €10.50 proposed last November. Minority shareholders have expressed positive sentiments towards the potential OPA, provided it is not an exclusionary offer. The renewed talks have led to an uptick in Grifols' stock price as investors and analysts react to the new developments surrounding the company.